Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 12Thoracic 8Lymphoid 8Gynecologic 7Other hematologic neoplasm 5Dermatologic 5Myeloid 4Genitourinary 4Breast 4Sarcoma 3Plasma cell 3Head & Neck 3CNS 3Tumor-Agnostic 2Other solid neoplasm 1NET 1Endocrine 1Classical hematology 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Everolimus 15Magnetic Resonance Spectroscopy 8lutetium Lu 177 dotatate 7pasireotide 5gallium Ga 68 dotatate 5Cisplatin 5Specimen Handling 4Positron Emission Tomography Computed Tomography 4Nivolumab 4Fluorodeoxyglucose F18 4Carboplatin 4Temozolomide 3Paclitaxel 3Octreotide 3Lutetium-177 3Ga(III)-DOTATOC 3Etoposide 3(177)Lu-DOTA-EB-TATE 3vandetanib 2pembrolizumab 2olaparib 2fluorodopa F 18 2dabrafenib 2copper dotatate CU-64 2cemiplimab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Trastuzumab 2Radiotherapy 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Disulfides × Endocrine × Clear all
NCT04609592 2025-09-09

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Stanford University

Phase 1 Recruiting
10 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡